Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Legend Biotech Corp
9LBCurrent price
44.8 EUR
+0.4 EUR (+0.90%)
Last closed
49.8 USD
Company
www.legendbiotech.com
ISIN
US52490G1022
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
8 845 328 384 USD
Yield for 12 month
-25.33 %
1Y
3Y
5Y
10Y
15Y
9LB
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
82.99 USDP/E ratio
–Dividend Yield
–Current Year
+285 143 000 USD
Last Year
+117 005 000 USD
Current Quarter
+186 523 000 USD
Last Quarter
+93 991 000 USD
Current Year
+120 478 000 USD
Last Year
+51 642 000 USD
Current Quarter
+130 703 000 USD
Last Quarter
+33 530 000 USD
Key Figures 9LB
1 year
3 years
5 years
10 years
EBITDA
-362 432 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-12.52 %
PEG Ratio
–
Return On Equity TTM
-22.21 %
Wall Street Target Price
82.99 USD
Revenue TTM
455 991 008 USD
Book Value
6.33 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
154.4 %
Dividend Yield
–
Gross Profit TTM
-284 006 000 USD
Earnings per share
-1.54 USD
Diluted Eps TTM
-1.54 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-62.5 %
Dividend Analytics 9LB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 9LB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 9LB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1000
Enterprise Value Revenue
17.3082
Price Sales TTM
19.398
Enterprise Value EBITDA
-15.3441
Price Book MRQ
7.6318
Financials 9LB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 9LB
For 52 weeks
38.6 USD
70.78 USD
50 Day MA
54.32 USD
Shares Short Prior Month
10 075 900
200 Day MA
54.53 USD
Short Ratio
10.27
Shares Short
10 711 247
Short Percent
11.18 %
BeatStart